Network Meta-analysis of Ravulizumab and Alternative Interventions for the Treatment of Neuromyelitis Optica Spectrum Disorder

  • Published on 07/10/2024
  •  Reading time: 6 min.

Stacey L. Clardy   1 , Sean J. Pittock 2 , Ina Zhang 9  

1 Department of Neurology, University of Utah, 175 Medical Drive North, Salt Lake City, UT, 84132, USA
2 Mayo Clinic, Rochester, MN, USA
9 PRECISIONheor, Oakland, CA, USA


Introduction Anti-aquaporin-4 antibody-positive (AQP4-Ab+) neuromyelitis optica spectrum disorder (NMOSD) is a complement-mediated autoimmune disease in which unpredictable and relapsing attacks on the central nervous system cause irreversible and accumulating damage. Comparative efficacy of new NMOSD therapies, such as ravulizumab, with established therapies is critical in making informed treatment decisions.
Methods Efficacy of ravulizumab relative to...


To continue reading this article in Full-Text...

* Access is totally free, without commitment or condition. Service exclusively reserved for healthcare professionals.

Peer-Reviewed Journals A-Z

Search | Advanced search

Get the latest news in Rare Diseases

Receive our newsletter to stay up to date with the latest news in Rare Diseases